Boston Scientific on Wednesday reduced its 2026 adjusted earnings projection and scaled back its outlook for full-year organic revenue growth, even after posting first-quarter results that narrowly beat analysts' forecasts.
The Marlborough, Massachusetts-based medical device maker now anticipates 2026 adjusted earnings of $3.34 to $3.41 per share, down from a prior range of $3.43 to $3.49 per share. Analysts were, on average, expecting $3.45 per share, according to LSEG data.
At the same time, Boston Scientific cut its full-year organic revenue growth guidance to a range of 6.5% to 8%, from an earlier forecast of 10% to 11%.
Quarterly results
For the quarter ended March 31, adjusted earnings came in at $0.80 per share, slightly above the consensus estimate of $0.79 per share. Revenue rose to $5.20 billion, compared with analysts' expectations of $5.17 billion.
Sales in Boston Scientific's cardiovascular division - the company's largest segment - totaled $3.50 billion, topping estimates of $3.43 billion. The company attributed strength in the segment to factors cited in its results, including increased physician adoption and technological advances supporting devices such as pacemakers and defibrillators.
Market response and analyst reactions
Shares experienced early volatility around the news and were little changed after the initial moves. Market participants and analysts reacted to the notable guidance revision.
Mike Kratky, an analyst at Leerink Partners, said, "Not surprising to see some initial pre-market volatility given the fairly steep guidance cut."
Robbie Marcus of J.P. Morgan highlighted the central question for investors: whether the lowered guidance reflects deteriorating trends into the second quarter and beyond or if it was a move to placate investors based on recent stock performance. He said, "There had been overwhelming investor calls to cut the guide, which the company did, yet the million-dollar question for the call is whether this is due to deteriorating trends in 2Q and beyond or just investor appeasement given how the stock has performed."
Strategic moves
Boston Scientific continues to expand its product portfolio through acquisitions. In January, the company agreed to acquire Penumbra in a $14.5 billion transaction, marking what the company described as its second-largest acquisition. The move is positioned to broaden Boston Scientific's heart device offerings and to re-enter the neurovascular market.
Context for investors
While the quarter delivered a small operational beat, the revised 2026 profit range and the narrower organic revenue growth forecast introduce questions about near-term momentum and investor expectations. Market reactions were muted after initial swings, and analysts are focused on whether the guidance adjustment signals a trend shift or a tactical response to shareholder pressure.
This report reflects the company-reported results, stated guidance ranges, and direct analyst comments as announced on the day of the earnings release.